Spring offer! Get NewsNow Essentials at just £2.99 a month (40% OFF!). Faster, slicker, customisable & ad free!Spring offer! Get NewsNow Essentials at just £2.99 a month (40% OFF!). Go ad free today!Spring offer! Upgrade now at £2.99/m (40% OFF!)

Home
Hot Topics
UK
World
Gaza
Ukraine
Iran
Climate Crisis
Business
Football
Sport
Entertainment
Tech
Science

Biogen
Biotech
AbbVie
Topics

Advertisement

Biogen

Share

Top Latest Popular

🗞️ NEWSNOW ESSENTIALS | Support independent news discovery ad free at just £2.99/m!

🗞️ NEWSNOW ESSENTIALS | Support independent news discovery ad free at just £2.99 a month!

Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss Manufacturing Chemist 3d

Manufacturing Chemist 3d

BIIB advances Alzheimer's disease drug despite study missing main goal Zacks 17:32 Fri, 15 May

Zacks 17:32 Fri, 15 May

Alzheimer's Pharma

Biogen patent suit targets somerset’s copy of spinraza therapy Bloomberg Law 6d

Bloomberg Law 6d

Advertisement

Italy probes Biogen for allegedly hindering sales of rival's MS drug The Tribune, California 21h

The Tribune, California 21h

Biogen forges on with Alzheimer’s therapy development despite Phase II miss Clinical Trials Arena 11:41 Fri, 15 May

Clinical Trials Arena 11:41 Fri, 15 May

Alzheimer's Pharma

Best healthcare stocks to buy in 2026 The Motley Fool 20:00 Thu, 14 May

The Motley Fool 20:00 Thu, 14 May

Novo Nordisk Alzheimer's

Advertisement

Advertisement

Latest

Yesterday

Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims FiercePharma 12:40 Wed, 27 May

Italy probes Biogen for allegedly hindering sales of rival's MS drug The Tribune, California 09:55 Wed, 27 May

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position Rock Hill Herald 07:50 Wed, 27 May

Monday

Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss Manufacturing Chemist 08:07 Mon, 25 May

Friday

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails Zacks 18:17 Fri, 22 May

Biogen, Denali Discontinue BIIB122 Development In Idiopathic Parkinson’s After Phase IIb Miss Scrip Pharma Intelligence 15:08 Fri, 22 May

Biogen and Denali report Phase IIb LUMA trial data for Parkinson’s Clinical Trials Arena 11:40 Fri, 22 May

Biogen And Denali Halt Development Of BIIB122 After Phase 2b Luma Study Misses Key Goals RTT News 09:19 Fri, 22 May

Biogen, Denali pull Parkinson's drug after failed trial pharmaphorum 08:57 Fri, 22 May

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study Rock Hill Herald 08:25 Fri, 22 May

Advertisement

Advertisement

Advertisement

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Industry Sectors Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna